The American company Novavax came up with a new vaccine against covid-19, which is comparable to those from Pfizer / BioNTech or Moderna. The vaccine showed efficacy above 90% in recent studies and no major side effects occurred in the vaccinees. Novavax could reach Europe during September. Until then, the company wants to apply to the public in the United States and the European Union for emergency use of the vaccine.
In addition, the new vaccine effectively targets all variants of coronavirus mutations, including the Indian and British mutations. The effectiveness of the substance has also been shown in the elderly or in people who have chronic health problems.
The new substance from Novavax has also been gaining attention in recent weeks because it could be distributed mainly to developing countries. The vaccine is not very difficult to store and, unlike some other vaccines, can be stored in normal refrigerators.
If approved by Novavax, the company would be able to produce 100 million doses per month. “Most of our first benefits will go to low- and middle-income countries. This has been our goal from the beginning,” said Stanav Erck, director of Novavax. The information was provided by the AP agency.
AstraZeneca should not be used in people over 60, an EMA official said. Watch the TV Nova report here: